Sichuan Kelun Pharmaceutical (002422) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 reached ¥4.96 billion, up 0.35% compared to the same quarter last year; year-to-date revenue was ¥16.79 billion, up 6.64% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥670.8 million, up 19.88% year-over-year; year-to-date net profit was ¥2.47 billion, up 25.85% year-over-year.

• Excluding non-recurring items, net profit for Q3 was ¥693.4 million, up 21.49% year-over-year; year-to-date was ¥2.45 billion, up 27.32%.

Financial highlights

• Gross margin improved as net profit growth outpaced revenue growth.

• Basic EPS for Q3 was ¥0.42, up 10.53% year-over-year; year-to-date EPS was ¥1.57, up 16.3%.

• Operating cash flow for Q3 was ¥3.28 billion, down 22.97% year-over-year.

• Total assets at quarter-end were ¥38.39 billion, up 5.31% from year-end; equity attributable to shareholders was ¥22.56 billion, up 14.65%.

Key financial ratios and metrics

• Weighted average ROE for Q3 was 3.00%, slightly down 0.08 percentage points year-over-year; year-to-date ROE was 11.32%, down 0.44 percentage points.

• Significant increase in capital reserve (up 35.12%) due to convertible bond conversion and H-share placement.